Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 1/2004

01-02-2004 | Case Report

Parvovirus B19-related chronic monoarthritis: immunohistochemical detection of virus-positive lymphocytes within the synovial tissue compartment: Two reported cases

Authors: Carsten Lennerz, Henning Madry, Sandra Ehlhardt, Thorsten Venzke, Klaus D. Zang, Yasmin Mehraein

Published in: Clinical Rheumatology | Issue 1/2004

Login to get access

Abstract

Apart from systemic symptoms of viral infection parvovirus B19, the infectious agent in erythema infectiosum, can lead to mainly self-limited acute and chronic arthropathy. Because mild subclinical features of the disease can be easily overlooked, joint affections might appear as isolated symptoms. We here report two cases of chronic monoarthritic symptoms of unknown origin, where immunohistochemical detection of B19-positive lymphocytic cells in the synovial tissue led to the diagnosis of B19 arthropathy. In conclusion, respective virus diagnostics should be considered even in chronic monosymptomatic arthritic lesions. The pathology of B19 arthropathy seems to be due to direct virus infection of cells within the synovia.
Literature
1.
Phillips PE (1997) Viral arthritis. Curr Opin Rheumatol 9:337–344PubMed
2.
Krause A, Kamradt T, Burmester GR (1996) Potential infectious agents in the induction of arthritides. Curr Opin Rheumatol 8:203–209
3.
Takeda T, Mizugaki Y, Matsubara L, Imai S, Koike T, Takada K (2000) Lytic Epstein–Barr virus infection in the synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 43:1218–1225CrossRefPubMed
4.
Kerr JR (2000) Pathogenesis of human parvovirus B19 in rheumatic disease. Ann Rheum Dis 59:672–683CrossRefPubMed
5.
Brown KE, Anderson SM, Young NS (1993) Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 262;114–117
6.
Young N (1988) Hematologic and hematopoietic consequences of B19 parvovirus infection. Semin Hematol 25:159–172PubMed
7.
Pillet S, Morinet F (2002) Parvovirus and erythroid cells. Pathol Biol (Paris) 50:349–356
8.
Mehraein Y, Rehder H, Draeger HG, Froster-Iskenius UG, Schwinger E, Holzgreve W (1991) Die Diagnostik fetaler Virusinfektionen durch in-situ-Hybridisierung. GeburtsFrauenheilkd 51:984–989
9.
Tolfvenstam T, Papadogiannakis N, Norbeck O, Petersson K, Broliden K (2001) Frequency of human parvovirus B19 infection in intrauterine fetal death. Lancet 357:1494–1497PubMed
10.
Modrow S, Dorsch S (2002) Antibody responses in parvovirus B19 infected patients. Pathol Biol (Paris) 50:326–331
11.
Cotmore SF, McKie VC, Anderson LJ, Astell CR, Tattersall P (1986) Identification of the major structural and nonstructural proteins encoded by human parvovirus B19 and mapping of their genes by procaryotic expression of isolated genomic fragments. J Virol 60:548–557PubMed
12.
White DG, Woolf AD, Mortimer PP, Cohen BJ, Blake DR, Bacon PA (1985) Human parvovirus arthropathy. Lancet 1:419–421CrossRefPubMed
13.
Naides SJ, Scharosch LL, Foto F, Howard EJ (1990) Rheumatologic manifestations of human parvovirus B19 infection in adults: Initial two-year clinical experience. Arthritis Rheum 33:1297–1309PubMed
14.
Naides SJ (1998) Rheumatic manifestations of parvovirus B19 infection. Rheum Dis Clin North Am 24:375–401
15.
Tyndall A, Jelk W, Hirsch HH (1994) Parvovirus B19 and erosive polyarthritis. Lancet 343:480–481CrossRef
16.
Fawaz-Estrup F (1996) Human parvovirus infection: rheumatic manifestation, angioedema, C1 esterase inhibitor deficiency, ANA positivity and possible onset of systemic lupus erythematosus. J Rheumatol 23:1180–1185PubMed
17.
Takahashi Y, Murai C, Shibata S et al. (1998) Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci USA 95:8227–8232CrossRefPubMed
18.
Speyer I, Breedveld FC, Dijkmans BA (1998) Human parvovirus B19 infection is not followed by inflammatory joint disease during long term follow up: A retrospective study of 54 patients. Clin Exp Rheumatol 16:576–578PubMed
19.
Altschuler EL (1999) Parvovirus B19 and the pathogenesis of rheumatoid arthritis: a case for historical reasoning. Lancet 354:1026–1027CrossRefPubMed
20.
Saal JG, Steidle M, Einsele H, Muller CA, Fritz P, Zacher J (1992) Persistence of B19 parvovirus in synovial membranes of patients with rheumatoid arthritis. Rheumatol Int 12:147–151PubMed
21.
Stahl H-D, Hubner B, Seidl B et al. (2000) Detection of multiple viral DNA species in synovial tissue and fluid of patients with early arthritis. Ann Rheum Dis 59:342–346CrossRefPubMed
22.
Nikkari S, Luukkainen R, Mottonen T et al. (1994) Does parvovirus B19 have a role in rheumatoid arthritis? Ann Rheum Dis 53:106–111PubMed
23.
Mehraein Y, Lennerz C, Ehlhardt S et al. (2003) Detection of parvovirus B19 capsid lytic proteins in lymphocytic cells in synovial tissue of autoimmune chronic arthritis. Mod Pathol 16(8):811–817
24.
Guillaume MP, Hermanus N, Peretz A (2002) Unusual Localisation of chronic arthropathy in umbar facet joints after parvovirus B19 infection. Clin Rheumatol 21:306–308CrossRefPubMed
25.
Naides SJ, Foto F, Marsh JL, Scharosch LL, Howard EJ (1991) Synovial tissue analysis in patients with chronic parvovirus B19 arthropathy. Clin Res 39:733A
Metadata
Title
Parvovirus B19-related chronic monoarthritis: immunohistochemical detection of virus-positive lymphocytes within the synovial tissue compartment: Two reported cases
Authors
Carsten Lennerz
Henning Madry
Sandra Ehlhardt
Thorsten Venzke
Klaus D. Zang
Yasmin Mehraein
Publication date
01-02-2004
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 1/2004
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-003-0800-8

Other articles of this Issue 1/2004

Clinical Rheumatology 1/2004 Go to the issue

Case Report

Two cases of hypertrophic pachymeningitis associated with myeloperoxidase antineutrophil cytoplasmic autoantibody (MPO-ANCA)-positive pulmonary silicosis in tunnel workers

Case Report

Polyarteritis nodosa and hypertrophic obstructive cardiomyopathy. A true association?

Original Article

Low bone mineral density in professional scuba divers

Case Report

Successful treatment of refractory adult-onset Still’s disease with infliximab. A prospective, non-comparative series of four patients

Case Report

An unusual pattern of arthritis in a child with Kawasaki syndrome

Review

The autonomic nervous system in systemic sclerosis. A review
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits